JNCCN study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer

(National Comprehensive Cancer Network) New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news